Plain-English translation of NCT02781584 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Liver disease research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial examined whether selonsertib, firsocostat, cilofexor, fenofibrate, and Vascepa—either taken individually or in pairs—could safely treat nonalcoholic fatty liver disease (NASH) in adults. Researchers studied different combinations of these medications to understand how well they worked and whether people could tolerate them over a 12-week period.
Fatty liver disease is a growing health problem with no approved medications currently available to treat it. This trial explored whether these new treatments could help reduce liver damage and slow the disease's progression in patients who need better options.
Participants received one of seven different medication regimens—either a single medication or a combination of two medications—taken orally once daily for 12 weeks. Throughout the trial, participants attended visits where researchers monitored their liver health through blood tests and imaging studies to track how safely the medication was working and whether their liver condition improved.
AI-generated summary from trial data · Aug 18, 2026 · Not medical advice
United States